Loading...
XKRX005500
Market cap153mUSD
Jan 03, Last price  
17,940.00KRW
1D
0.56%
1Q
-2.92%
Jan 2017
-48.37%
Name

Samjin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:005500 chart
P/E
11.89
P/S
0.77
EPS
1,509.16
Div Yield, %
4.71%
Shrs. gr., 5y
1.04%
Rev. gr., 5y
2.36%
Revenues
292.13b
+6.60%
137,112,663,000147,996,742,000165,388,711,000200,410,515,000201,756,103,660185,702,080,230192,006,713,100201,305,289,860216,511,471,520239,312,893,940245,271,927,860260,016,571,280241,926,177,090235,164,889,490250,070,355,500274,031,808,450292,128,533,737
Net income
18.91b
-13.65%
6,434,603,0006,731,815,0007,044,974,00010,477,195,0007,062,463,89010,638,443,4907,878,193,57020,716,717,57027,043,171,46030,174,331,51035,795,824,75025,526,185,48011,880,757,00027,879,308,25028,404,156,00021,893,835,62018,905,784,040
CFO
8.33b
-51.81%
-5,744,629,000-1,503,696,0002,135,391,00016,835,715,00012,670,311,56033,931,501,2207,374,337,48032,406,391,92018,935,641,49048,657,842,14037,283,674,16030,081,823,68023,633,082,80023,860,500,18023,967,389,57017,293,228,4508,333,560,990
Dividend
Dec 27, 2023800 KRW/sh
Earnings
Mar 12, 2025

Profile

Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.
URL
https://www.samjinpharm.co.kr/
IPO date
Jun 18, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
292,128,534
6.60%
274,031,808
9.58%
Cost of revenue
252,340,668
202,665,459
Unusual Expense (Income)
NOPBT
39,787,866
71,366,349
NOPBT Margin
13.62%
26.04%
Operating Taxes
(3,348,649)
3,325,332
Tax Rate
4.66%
NOPAT
43,136,515
68,041,017
Net income
18,905,784
-13.65%
21,893,836
-22.92%
Dividends
(10,584,730)
(9,842,141)
Dividend yield
3.78%
3.03%
Proceeds from repurchase of equity
(9,992,509)
25,006,501
BB yield
3.57%
-7.69%
Debt
Debt current
114,314,381
44,841,710
Long-term debt
4,962,366
43,349,838
Deferred revenue
Other long-term liabilities
5,662,073
5,224,771
Net debt
56,547,205
24,735,651
Cash flow
Cash from operating activities
8,333,561
17,293,228
CAPEX
(20,721,232)
(35,497,922)
Cash from investing activities
(18,247,172)
(70,057,357)
Cash from financing activities
9,973,667
47,164,864
FCF
30,096,203
39,243,847
Balance
Cash
4,006,474
4,662,783
Long term investments
58,723,068
58,793,114
Excess cash
48,123,115
49,754,307
Stockholders' equity
254,759,937
457,660,861
Invested Capital
341,542,289
310,892,582
ROIC
13.22%
22.94%
ROCE
10.21%
19.73%
EV
Common stock shares outstanding
12,954
12,671
Price
21,600.00
-15.79%
25,650.00
-2.47%
Market cap
279,806,854
-13.91%
325,020,820
0.45%
EV
340,736,390
350,276,591
EBITDA
56,400,622
81,182,404
EV/EBITDA
6.04
4.31
Interest
4,425,475
1,763,239
Interest/NOPBT
11.12%
2.47%